Background: Atypical antipsychotics, like risperidone purportedly, score over their typical counterparts in terms of their lower propensity toward producing extrapyramidal symptoms (EPS). However, recent studies have furnished evidence to the contrary. Hereby, we present a case series implicating risperidone as the causative agent for EPS. Methods: As a part of the pharmacovigilance programme of India, the authors have assessed 10 physician-reported cases of EPS among the 1,830 patients who were prescribed risperidone within the time period of January 2012-December 2014 in a tertiary care hospital in South India. Causality, severity, and preventability assessments of adverse reaction were done as per Naranjo's, Hartwig's, and Thornton'scale respectively. Results: Of the 10 cases, a dose-dependent occurrence of EPS was noted in all and the time duration for development of EPS ranged from 1 week to 2 years. Four patients developed EPS at a dose of 6-8 mg, 4 developed at a dose of 4-6 mg, and the remaining 2 developed at 2 and 1 mg. Conclusion: A strong temporal correlation between risperidone and EPS was noted in all cases. High doses produced EPS early, whereas moderate to low doses produced EPS at a later date. Thus, cautious use and close monitoring are warranted in the chronic use of risperidone.

Keywords:
Atypical antipsychotic, Anticholinergic, Bipolar disorder, Cog wheel rigidity
1.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
2.
Suenaga T, Tawara Y, Goto S, Kouhata S, Kagaya A, Horiguchi J, et al: Risperidone treatment of neuroleptic-induced tardive extrapyramidal symptoms. Int J Psychiatry Clin Pract 2000;4:241-243.
3.
Novick D, Haro JM, Bertsch J, Haddad PM: Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol 2010;30 531-540.
4.
Divac N, Prostran M, Jakovcevski I, Cerovac N: Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int 2014;2014:656370.
5.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
6.
Hartwig SC, Siegel J, Schneider PJ: Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-2232.
7.
Schumock GT, Seeger JD, Kong SX: Control charts to monitor rates of adverse drug reactions. Hosp Pharm 1995;30:1088, 1091-1092, 1095-1096.
8.
Jeste DV, Wyatt RJ: Understanding and treating Tardive Dyskinesia. Psychiatric Services 1982;34:1065-1066.
9.
Nobutomo Yamamoto and Toshiya Inada: Dystonia Secondary to Use of Antipsychotic Agents, Dystonia - The Many Facets, Prof. Raymond Rosales edition 2012. http://www.intechopen.com/books/dystonia-the-many-facets/dystonia-secondary-to-use-of-antipsychoticagents (assessed September 4, 2016).
10.
Karki SD, Masood GR: Combination risperidone and SSRI-induced serotonin syndrome. Ann Pharmacother 2003;37:388-391.
11.
Sotto Mayor J, Pacheco AP, Esperanca S, Oliveira e Silva A: Trazodone in the elderly: risk of extrapyramidal acute events. BMJ Case Rep 2015;2015:pii:bcr2015210726.
12.
Dutta BK, Saha A, Nagesh IV. Extrapyramidal symptoms after fluoxetine. Med J Armed Forces India 2015;71(suppl 1):S99-S100.
13.
Shin HW, Chung SJ: Drug-induced parkinsonism. J Clin Neurol 2012;8:15-21.
14.
Bobes J, Rejas J, Garcia-Garcia M, et al: Frequency of extrapyramidal adverse reactions in schizophrenic outpatients treated with risperidone, olanzapine, quetiapine or haloperidol. Clin Drug Invest 2002;22:609-622.
15.
Miyamoto S, Duncan GE, Marx CE, Lieberman JA: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79-104.
16.
Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al: Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-1087.
17.
Wirshing DA, Wirshing WC, Marder SR, Saunders CS, Rossotto EH, Erhart SM: Atypical antipsychotics: a practical review. Medscape Psychiatry Mental Health J 1997;2.
18.
Ammar HO, Ghorab MM, Mahmoud AA, Noshi SH: Formulation of risperidone in floating microparticles to alleviate its extrapyramidal side effects. Future J Pharm Sci 2016;2:43-59.
19.
Mas S, Gasso P,Ritter MA, Malagelada C, Bernardo M, Lafuente A: Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: Multilocus interaction in the mTOR pathway. Eur Neuropsychopharmacol 2015;25:51-59.
20.
Gründer G, Hippius H, Carlsson A: The ‘atypicality' of antipsychotics: a concept re-examined and re-defined. Nature Reviews Drug Discovery 2009;8:197-202.
21.
Fusar PP, Kempton MJ, Rosenheck RA: Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 2013;28:57-66.
22.
Bo QJ, Li XB, Wang ZM, Li AN, Ma X, Wang CY: Extrapyramidal symptoms during risperidone maintenance treatment in schizophrenia: a prospective, multicenter study. J Clin Psychopharmacol 2016;36:125-129.
23.
McGorry PD, Cocks J, Power P, Burnett P, Harrigan S, Lambert T: Very low-dose risperidone in first-episode psychosis: a safe and effective way to initiate treatment. Schizophr Res Treatment 2011;2011:631690.
24.
Rybakowski JK, Vansteelandt K, Remlinger-Molenda A, Fleischhacker WW, Kahn RS, Peuskens J; EUFEST Study Group: Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST. Eur Neuropsychopharmacol 2014;24:1500-1505.
25.
Kopala LC, Good KP, Honer WG: Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997;17:308-313.
26.
Merlo MC, Hofer H, Gekle W, Berger G, Ventura J, Panhuber I, Latour G, Marder SR: Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. J Clin Psychiatry 2002;63:885-891.
27.
Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G: Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005;162:947-953.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.